104 related articles for article (PubMed ID: 18262286)
21. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
22. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
Sfikakis PP; Karali V; Lilakos K; Georgiou G; Panayiotidis P
Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
[TBL] [Abstract][Full Text] [Related]
23. Novel roles for murine complement receptors type 1 and 2 I. Regulation of B cell survival and proliferation by CR1/2.
Molnár E; Erdei A; Prechl J
Immunol Lett; 2008 Mar; 116(2):156-62. PubMed ID: 18243341
[TBL] [Abstract][Full Text] [Related]
24. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Simon D; Czömpöly T; Berki T; Minier T; Peti A; Tóth E; Czirják L; Németh P
Int Immunol; 2009 Apr; 21(4):415-22. PubMed ID: 19211583
[TBL] [Abstract][Full Text] [Related]
25. The role of innate immunity in the induction of autoimmunity.
Pisetsky DS
Autoimmun Rev; 2008 Oct; 8(1):69-72. PubMed ID: 18708168
[TBL] [Abstract][Full Text] [Related]
26. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
27. Targeting of B cells in SLE: rationale and therapeutic opportunities.
Silverman GJ
Bull NYU Hosp Jt Dis; 2006; 64(1-2):51-6. PubMed ID: 17121490
[TBL] [Abstract][Full Text] [Related]
28. Insertion of a targeting peptide on capsid surface loops of human papillomavirus type-16 virus-like particles mediate elimination of anti-dsDNA Abs-producing B cells with high efficiency.
Wang H; Yang Z; Li F; He Y; Wang S; Yang D; Wu Y
J Immunother; 2009 Jan; 32(1):36-41. PubMed ID: 19307992
[TBL] [Abstract][Full Text] [Related]
29. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Singh V; Mahoney JA; Petri M
J Rheumatol; 2008 Oct; 35(10):1989-93. PubMed ID: 18709693
[TBL] [Abstract][Full Text] [Related]
30. Antibody clustering helps refine lupus prognosis.
Kessel A; Rosner I; Halasz K; Grushko G; Shoenfeld Y; Paran D; Toubi E
Semin Arthritis Rheum; 2009 Aug; 39(1):66-70. PubMed ID: 18538829
[TBL] [Abstract][Full Text] [Related]
31. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation.
Garaud S; Le Dantec C; Jousse-Joulin S; Hanrotel-Saliou C; Saraux A; Mageed RA; Youinou P; Renaudineau Y
J Immunol; 2009 May; 182(9):5623-32. PubMed ID: 19380809
[TBL] [Abstract][Full Text] [Related]
32. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
[TBL] [Abstract][Full Text] [Related]
33. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
[TBL] [Abstract][Full Text] [Related]
34. Generation of a human IgG3-streptavidin fusion protein. Implications for the inhibition and elimination of auto-reactive B cells.
Preissler MT; Walsh MC; Banas JA; Gallagher DJ; Gosselin EJ
Hum Antibodies; 2003; 12(3):77-92. PubMed ID: 14646036
[TBL] [Abstract][Full Text] [Related]
35. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus.
Lartigue A; Colliou N; Calbo S; François A; Jacquot S; Arnoult C; Tron F; Gilbert D; Musette P
J Immunol; 2009 Nov; 183(10):6207-16. PubMed ID: 19841185
[TBL] [Abstract][Full Text] [Related]
36. BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus.
Bardin N; Desplat-Jego S; Daniel L; Jourde Chiche N; Sanmarco M
Autoimmunity; 2009 Jan; 42(1):63-8. PubMed ID: 19127456
[TBL] [Abstract][Full Text] [Related]
37. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies.
Voss A; Nielsen EH; Svehag SE; Junker P
J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838
[TBL] [Abstract][Full Text] [Related]
38. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus.
Hoffman IE; Lauwerys BR; De Keyser F; Huizinga TW; Isenberg D; Cebecauer L; Dehoorne J; Joos R; Hendrickx G; Houssiau F; Elewaut D
Ann Rheum Dis; 2009 Mar; 68(3):412-5. PubMed ID: 18930995
[TBL] [Abstract][Full Text] [Related]
39. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
Muller S; Monneaux F; Schall N; Rashkov RK; Oparanov BA; Wiesel P; Geiger JM; Zimmer R
Arthritis Rheum; 2008 Dec; 58(12):3873-83. PubMed ID: 19035498
[TBL] [Abstract][Full Text] [Related]
40. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease.
Schett G; Dumortier H; Hoefler E; Muller S; Steiner G
Ann Rheum Dis; 2009 May; 68(5):729-35. PubMed ID: 18495733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
